抽象
BackgroundCurrent guidelines suggest treating cancer patients with incidental pulmonary embolism (PE) similar to those with clinically-suspected and confirmed PE. However, the natural history of these presentations has not been thoroughly compared.
方法我们使用RIETE登记处的数据进行比较活跃癌症和偶然PE患者的3个月结果versusthose with clinically-suspected and confirmed PE. The primary outcome was 90-day all-cause mortality. Secondary outcomes were PE-related mortality, symptomatic PE recurrences and major bleeding.
结果From July 2012 to January 2019, 946 cancer patients with incidental asymptomatic PE and 2274 with clinically-suspected and confirmed PE were enrolled. Most patients (95%versus90%) received low-molecular-weight heparin therapy. During the first 90 days, 598 patients died, including 42 from PE. Patients with incidental PE had a lower all-cause mortality rate than those with suspected and confirmed PE (11%versus22%; odds ratio [OR]: 0.43; 95%CI: 0.34–0.54). Results were consistent for PE-related mortality (0.3%versus1.7%;或者:0.18;95%CI:0.06-0.59)。多变量分析证实,偶然PE的患者处于较低的风险下死亡(调节或:0.43; 95%CI:0.34-0.56)。总体而言,29名患者(0.9%)出现症状性PE复发,122(3.8%)具有重大出血。体育复发没有显着差异(或:0.62; 95%CI:0.25-1.54)或重大出血(或:0.78; 95%CI:0.51-1.18)。
Conclusions患有临床和证实PE的死亡率低的癌症率较低。需要进一步的研究来验证这些调查结果,并探讨这些患者的最佳管理策略。
脚注
此手稿最近被接受了出版物欧洲呼吸杂志. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of theerj.线上。请打开或下载PDF以查看本文。
Conflict of interest: Dr. Girkin reports grants, personal fees and non-financial support from Ena Therapeutics Pty Ltd, during the conduct of the study; In addition, Dr. Girkin has a patent PCT/AU2018/050295 issued.
利益冲突:Peris博士无需披露。
利益冲突:López-nuñez博士无需披露。
Conflict of interest: Dr. Maestre has nothing to disclose.
利益冲突:Jiménez博士无需披露。
利益冲突:穆里尔博士无需披露。
利益冲突:比基德博士报告,他是代表原告的咨询专家,诉讼与特定类型的IVC过滤器相关的诉讼。
利益冲突:温伯格博士无关disclose.
Conflict of interest: Dr. Ay has nothing to disclose.
利益冲突:Mazzolai博士无需披露。
利益冲突:Lorenzo博士无需披露。
利益冲突:蒙利利博士无需披露。
- 收到July 10, 2020.
- AcceptedNovember 30, 2020.
- 复制right ©ERS 2020